Sequestration of Vascular Endothelial Growth Factor (VEGF) Induces Late Restrictive Lung Disease

被引:8
|
作者
Wieck, Minna M. [1 ]
Spurrier, Ryan G. [1 ]
Levin, Daniel E. [1 ]
Mojica, Salvador Garcia [1 ]
Hiatt, Michael J. [2 ]
Reddy, Raghava [2 ]
Hou, Xiaogang [1 ]
Navarro, Sonia [2 ,3 ]
Lee, Jooeun [2 ]
Lundin, Amber [2 ]
Driscoll, Barbara [2 ,4 ]
Grikscheit, Tracy C. [1 ,2 ]
机构
[1] Childrens Hosp Los Angeles, Saban Res Inst, Div Pediat Surg, Los Angeles, CA 90027 USA
[2] Childrens Hosp Los Angeles, Dev Biol & Regenerat Med Program, Saban Res Inst, Los Angeles, CA 90027 USA
[3] Univ So Calif, Herman Ostrow Sch Dent, Los Angeles, CA USA
[4] Univ So Calif, Keck Sch Med, Integrat Biol Dis Grad Program, Los Angeles, CA 90033 USA
来源
PLOS ONE | 2016年 / 11卷 / 02期
关键词
RESPIRATORY-DISTRESS; DOWN-REGULATION; CROSS-TALK; EXPRESSION; INHIBITION; ANGIOGENESIS; HYPEROXIA; CELLS; MMP-9; EPITHELIUM;
D O I
10.1371/journal.pone.0148323
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Rationale Neonatal respiratory distress syndrome is a restrictive lung disease characterized by surfactant deficiency. Decreased vascular endothelial growth factor (VEGF), which demonstrates important roles in angiogenesis and vasculogenesis, has been implicated in the pathogenesis of restrictive lung diseases. Current animal models investigating VEGF in the etiology and outcomes of RDS require premature delivery, hypoxia, anatomically or temporally limited inhibition, or other supplemental interventions. Consequently, little is known about the isolated effects of chronic VEGF inhibition, started at birth, on subsequent developing lung structure and function. Objectives To determine whether inducible, mesenchyme-specific VEGF inhibition in the neonatal mouse lung results in long-term modulation of AECII and whole lung function. Methods Triple transgenic mice expressing the soluble VEGF receptor sFlt-1 specifically in the mesenchyme (Dermo-1/rtTA/sFlt-1) were generated and compared to littermate controls at 3 months to determine the impact of neonatal downregulation of mesenchymal VEGF expression on lung structure, cell composition and function. Reduced tissue VEGF bioavailability has previously been demonstrated with this model. Measurements and Main Results Triple transgenic mice demonstrated restrictive lung pathology. No differences in gross vascular development or protein levels of vascular endothelial markers was noted, but there was a significant decrease in perivascular smooth muscle and type I collagen. Mutants had decreased expression levels of surfactant protein C and hypoxia inducible factor 1-alpha without a difference in number of type II pneumocytes. Conclusions These data show that mesenchyme-specific inhibition of VEGF in neonatal mice results in late restrictive disease, making this transgenic mouse a novel model for future investigations on the consequences of neonatal RDS and potential interventions.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
    Barratt, Shaney L.
    Flower, Victoria A.
    Pauling, John D.
    Millar, Ann B.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (05)
  • [2] VASCULAR ENDOTHELIAL GROWTH FACTOR ( VEGF) INDUCES OSTEOCLASTOGENESIS IN RHEUMATOID ARTHRITIS
    Kim, H. -R.
    Lee, S. -H.
    Kim, H. -Y.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 206 - 206
  • [3] Distribution of vascular endothelial growth factor (VEGF) in prostate disease
    Walsh, K
    Sriprasad, S
    Hopster, D
    Codd, J
    Mulvin, D
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2002, 5 (02) : 119 - 122
  • [4] Distribution of vascular endothelial growth factor (VEGF) in prostate disease
    K Walsh
    S Sriprasad
    D Hopster
    J Codd
    D Mulvin
    [J]. Prostate Cancer and Prostatic Diseases, 2002, 5 : 119 - 122
  • [5] Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Inhibitors in Health and Disease
    Broussy, Sylvain
    [J]. PHARMACEUTICALS, 2024, 17 (07)
  • [6] Scleroderma alveolitis: A vascular endothelial growth factor (VEGF) deficiency-related lung disease?
    de Santis, M.
    Peluso, G.
    Capoluongo, E.
    Inzitari, R.
    Tolusso, B.
    Bosello, S.
    Alivernini, S.
    Pinnelli, M.
    Zuppi, C.
    Castagnola, M.
    Ferraccioli, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 : A24 - A24
  • [7] Vascular endothelial growth factor (VEGF) induces human Langerhans cell migration
    Staquet, MJ
    Godefroy, S
    Jacquet, C
    Viac, J
    Schmitt, D
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2001, 293 (1-2) : 26 - 28
  • [8] Vascular endothelial growth factor (VEGF) induces human Langerhans cell migration
    M. J. Staquet
    Sylvie Godefroy
    Christelle Jacquet
    Jacqueline Viac
    Daniel Schmitt
    [J]. Archives of Dermatological Research, 2001, 293 : 26 - 28
  • [9] Vascular permeability factor/vascular endothelial growth factor-A (VPF/VEGF, VEGF-A) induces lymphangiogenesis as well as angiogenesis
    Nagy, JA
    Vasile, E
    Brown, LF
    Manseau, EJ
    Eckelhoefer, IA
    Bliss, SH
    Dvorak, AK
    Dvorak, HF
    [J]. FASEB JOURNAL, 2002, 16 (04): : A367 - A367
  • [10] Expression Of Vascular Endothelial Growth Factor (VEGF) And Vascular Endothelial Growth Factor Receptors (VEGFRs) In Lung Tissue Of Smokers And COPD Patients
    Lee, S. H.
    Lee, E. J.
    Hur, G. Y.
    Lee, S. Y.
    Lee, S. Y.
    Kim, J. H.
    Shin, C.
    Shim, J. J.
    In, K. H.
    Kang, K. H.
    Yoo, S. H.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183